Grace Therapeutics
GRCE
20 hedge funds and large institutions have $11M invested in Grace Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.8% less ownership
Funds ownership: 27.6% → 26.8% (-0.8%)
3% less capital invested
Capital invested by funds: $11.3M → $11M (-$311K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$545K |
| 2 |
Renaissance Technologies
New York
|
+$178K |
| 3 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$43.9K |
| 4 |
Citigroup
New York
|
+$8.64K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$812 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$694K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$255K |
| 3 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
-$144K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22.3K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
-$86 |
GRCE Hedge Fund Activity: Q3 2025 in Review
20 of the 7,646 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2025, worth a combined $11M — down 2.7% from $11.3M a quarter earlier.
Fund positioning in GRCE was balanced in Q3 2025: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $545K. The largest seller was AIGH Capital Management, cutting an estimated $694K.
- 20 institutional investors held Grace Therapeutics (GRCE) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $11M of Grace Therapeutics stock for Q3 2025, down 2.7% quarter-over-quarter.
- 2 funds opened new Grace Therapeutics positions in Q3 2025 and 2 closed out, a net change of 0 holders.
- The largest Grace Therapeutics buyer in Q3 2025 was ADAR1 Capital Management, an estimated $545K added.
- The largest Grace Therapeutics seller in Q3 2025 was AIGH Capital Management, an estimated $694K sold.
Based on aggregated 13F filings for Q3 2025.